Furthermore, the combination of NKG2D-CAR-NK cell therapy with an anti-HER2/NKG2D bispecific antibody exhibited remarkable anti-cancer effectiveness, even in cases of HER2-positive tumors lacking NKG2DL expression [606]. This evidence concerns the gene KLRK1 and cancer.